MX2022000356A - Compuesto para tratamiento de combinacion. - Google Patents

Compuesto para tratamiento de combinacion.

Info

Publication number
MX2022000356A
MX2022000356A MX2022000356A MX2022000356A MX2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A
Authority
MX
Mexico
Prior art keywords
compound
combination treatment
treatment
combination
anxiety
Prior art date
Application number
MX2022000356A
Other languages
English (en)
Inventor
Ulf Simonsen
Simon Comerma-Steffensen
Dan Peters
Original Assignee
Initiator Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Initiator Pharma As filed Critical Initiator Pharma As
Publication of MX2022000356A publication Critical patent/MX2022000356A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un compuesto para el tratamiento de una enfermedad o trastorno que implica depresión, disfunción eréctil, ansiedad, disfunción sexual y/o trastornos eyaculatorios; o una combinación de los mismos.
MX2022000356A 2019-08-06 2020-08-06 Compuesto para tratamiento de combinacion. MX2022000356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190224 2019-08-06
PCT/EP2020/072092 WO2021023805A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Publications (1)

Publication Number Publication Date
MX2022000356A true MX2022000356A (es) 2022-05-11

Family

ID=67551141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000356A MX2022000356A (es) 2019-08-06 2020-08-06 Compuesto para tratamiento de combinacion.

Country Status (16)

Country Link
US (1) US20220288052A1 (es)
EP (2) EP4009942B1 (es)
JP (1) JP2022544463A (es)
KR (1) KR20220054593A (es)
CN (1) CN114430679A (es)
AU (1) AU2020326244A1 (es)
BR (1) BR112022002169A2 (es)
CA (1) CA3146837A1 (es)
DK (1) DK4009942T3 (es)
ES (1) ES2962648T3 (es)
FI (1) FI4009942T3 (es)
IL (1) IL290319B2 (es)
MX (1) MX2022000356A (es)
PL (1) PL4009942T3 (es)
WO (1) WO2021023805A1 (es)
ZA (1) ZA202200723B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552919A (en) * 2004-09-30 2010-06-25 Neurosearch As Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2010513392A (ja) * 2006-12-20 2010-04-30 ノイロサーチ アクティーゼルスカブ 新規クロメン−２−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
AU2009284169A1 (en) * 2008-08-21 2010-02-25 Neurosearch A/S Treatment of anxiety disorders
WO2011092061A1 (en) * 2010-01-29 2011-08-04 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
IL290319A (en) 2022-04-01
EP4009942A1 (en) 2022-06-15
JP2022544463A (ja) 2022-10-19
ZA202200723B (en) 2022-08-31
US20220288052A1 (en) 2022-09-15
CA3146837A1 (en) 2021-02-11
IL290319B2 (en) 2023-06-01
DK4009942T3 (da) 2023-10-23
EP4009942B1 (en) 2023-08-09
EP4241839A3 (en) 2023-11-15
FI4009942T3 (fi) 2023-09-26
ES2962648T3 (es) 2024-03-20
WO2021023805A1 (en) 2021-02-11
EP4241839A2 (en) 2023-09-13
CN114430679A (zh) 2022-05-03
PL4009942T3 (pl) 2024-04-08
AU2020326244A1 (en) 2022-03-17
BR112022002169A2 (pt) 2022-06-07
KR20220054593A (ko) 2022-05-03

Similar Documents

Publication Publication Date Title
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2023009611A (es) Esteroides neuroactivos, y su metodo de uso.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
GEP20207167B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
PH12015502788A1 (en) Antibody formulations and methods
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
MX2011013260A (es) Apomorfina sublingual.
JOP20190096A1 (ar) مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي y
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2020006385A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos que comprenden una demencia.
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MX2022009366A (es) Compuestos y usos de estos.
MX2021003515A (es) Compuestos polimorficos y usos de los mismos.
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
MX2022005084A (es) Formas sólidas de un modulador del receptor s1p a.
MX2019011692A (es) Nuevo tratamiento de enfermedades mitocondriales.
MX2021007460A (es) Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados.
MX2022000356A (es) Compuesto para tratamiento de combinacion.